Australia's most trusted
source of pharma news
Friday, 08 August 2025
Posted 5 August 2025 AM
An update from PBAC Chair, Professor Robyn Ward, after the Committee's July meeting has revealed three of the toughest questions facing pharma, remain unanswered.
Equitable access to obesity medicines, two PDL-1 tumour agnositic listing proposals and shifting medicines from the Life Saving Drugs Program (LSDP) to the PBS remain on the PBAC's to-do list.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.